At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 57 enrolled
Drug / intervention
BI 1026706 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase I Trial in Healthy Male Current Smoker Subjects to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response and Safety of 4 Weeks Oral Administration of BI 1026706
In Brief
A Phase 1 clinical trial evaluating BI 1026706 and Placebo for Healthy. Completed, enrolled 57 participants across 1 site.
Detailed Summary
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionFeb 2017
Study CompletionMar 2017
TodayJul 2026
First PostedJan 15, 2016
Enrollment StartMar 11, 2016
Primary CompletionFeb 14, 2017
Study CompletionMar 13, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.5 years ago
Interventions
BI 1026706drug
Placebodrug